Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
Status:
Not yet recruiting
Trial end date:
2025-12-29
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to characterize the safety and tolerability of tucatinib
(MK-7119) in Chinese participants with human epidermal growth factor receptor 2 positive
(HER2+) advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma (GEC),
and colorectal cancer.